94 related articles for article (PubMed ID: 20136591)
21. Treatment of extraintestinal manifestations in inflammatory bowel disease.
Lakatos PL; Lakatos L; Kiss LS; Peyrin-Biroulet L; Schoepfer A; Vavricka S
Digestion; 2012; 86 Suppl 1():28-35. PubMed ID: 23051724
[TBL] [Abstract][Full Text] [Related]
22. Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues.
Bosè F; Raeli L; Garutti C; Frigerio E; Cozzi A; Crimi M; Caprioli F; Scavelli R; Altomare G; Geginat J; Abrignani S; Reali E
Clin Immunol; 2011 May; 139(2):164-76. PubMed ID: 21334981
[TBL] [Abstract][Full Text] [Related]
23. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.
Ben-Horin S; Mazor Y; Yanai H; Ron Y; Kopylov U; Yavzori M; Picard O; Fudim E; Maor Y; Lahat A; Coscas D; Eliakim R; Dotan I; Chowers Y
Aliment Pharmacol Ther; 2012 Mar; 35(6):714-22. PubMed ID: 22288419
[TBL] [Abstract][Full Text] [Related]
24. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
[TBL] [Abstract][Full Text] [Related]
25. [Extraintestinal manifestations in inflammatory bowel disease].
Larsen S; Bendtzen K; Nielsen OH
Ugeskr Laeger; 2009 Oct; 171(43):3078-83. PubMed ID: 19852894
[TBL] [Abstract][Full Text] [Related]
26. New therapeutic approach in inflammatory bowel disease.
Papa A; Mocci G; Scaldaferri F; Bonizzi M; Felice C; Andrisani G; Gasbarrini A
Eur Rev Med Pharmacol Sci; 2009 Mar; 13 Suppl 1():33-5. PubMed ID: 19530509
[TBL] [Abstract][Full Text] [Related]
27. Maximizing the effect of biologics in inflammatory bowel disease.
Souto Rodriguez R; Swoger JM; Barreiro-De Acosta M; Regueiro M
Minerva Gastroenterol Dietol; 2012 Jun; 58(2):101-22. PubMed ID: 22643594
[TBL] [Abstract][Full Text] [Related]
28. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
Van Assche G; Rutgeerts P
Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
[TBL] [Abstract][Full Text] [Related]
29. Tumor necrosis factor inhibitors for rheumatoid arthritis.
Jones RE; Moreland LW
Bull Rheum Dis; 1999; 48(3):1-4. PubMed ID: 10408141
[TBL] [Abstract][Full Text] [Related]
30. Tumour necrosis factor inhibitors in ankylosing spondylitis.
Reed MR; Taylor AL
Intern Med J; 2008 Oct; 38(10):781-9. PubMed ID: 18422565
[TBL] [Abstract][Full Text] [Related]
31. [Rheumatoid arthritis: current status of therapy].
El Bahri DM; Meddeb N; Sellami S
Tunis Med; 2007 Jan; 85(1):1-8. PubMed ID: 17424701
[TBL] [Abstract][Full Text] [Related]
32. Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation.
De Keyser F; Van Damme N; De Vos M; Mielants H; Veys EM
Inflamm Res; 2000 Feb; 49(2):47-54. PubMed ID: 10738942
[TBL] [Abstract][Full Text] [Related]
33. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience.
Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Wittmann T
J Gastrointestin Liver Dis; 2012 Sep; 21(3):265-9. PubMed ID: 23012667
[TBL] [Abstract][Full Text] [Related]
34. [Musculoskeletal Manifestation in Inflammatory Bowel Disease].
Kim YS; Lee J
Korean J Gastroenterol; 2019 May; 73(5):276-284. PubMed ID: 31132834
[TBL] [Abstract][Full Text] [Related]
35. Review article: Pathophysiology of the intestinal mucosa in inflammatory bowel disease and arthritis: similarities and dissimilarities in clinical findings.
Orchard T; Jewell DP
Aliment Pharmacol Ther; 1997 Dec; 11 Suppl 3():10-5; discussion 15-6. PubMed ID: 9467974
[TBL] [Abstract][Full Text] [Related]
36. Joint expedition: linking gut inflammation to arthritis.
Jacques P; Elewaut D
Mucosal Immunol; 2008 Sep; 1(5):364-71. PubMed ID: 19079200
[TBL] [Abstract][Full Text] [Related]
37. Gastrointestinal issues in children with rheumatologic disease.
Chehade M; Benkov K
Curr Rheumatol Rep; 2002 Dec; 4(6):458-65. PubMed ID: 12427359
[TBL] [Abstract][Full Text] [Related]
38. Bowel inflammation and the spondyloarthropathies.
De Keyser F; Elewaut D; De Vos M; De Vlam K; Cuvelier C; Mielants H; Veys EM
Rheum Dis Clin North Am; 1998 Nov; 24(4):785-813, ix-x. PubMed ID: 9891711
[TBL] [Abstract][Full Text] [Related]
39. [Arthrosis: pathologic review and the place of non-steroidal anti-inflammatory agents in its treatment].
Franchimont P; Bassleer C
Rev Med Liege; 1987 Nov; 42(22):873-80. PubMed ID: 3321323
[No Abstract] [Full Text] [Related]
40. Clinico-pathological correlation of non specific inflammation in bowel histology with joint manifestation in a tertiary center in South India.
Goel R; Danda D; Avinash B; Pulimood AB; Mathew J; Ramakrishna BS
Rheumatol Int; 2013 Aug; 33(8):2149-52. PubMed ID: 22258457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
